US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Fidelity Disruptive Medicine ETF

32.29

-0.2439-0.75%

Volume:4K

Turnover:131.92K

Market Cap:52.42M

PE:- -

High:32.47

Open:32.47

Low:32.03

Close:32.53

52wk High:32.89

52wk Low:23.48

Shares:1.62M

Float Shares:1.62M

Volume Ratio:0.47

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading

MT Newswires Live

Cytek Biosciences Shares Drop After Jury Says it Owes $56 Million in Damages

Qiagen Names Jonathan Pratt as CEO, Effective Sept. 1

Canada's Nanalysis Q2 Revenue Edges up on Services Strength

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

Cytek Owes Beckman Coulter $56 Mln in Cell-Analysis Patent Case, US Jury Says

William O'Neil Initiates Thermo Fisher Scientific at Buy

MT Newswires Live

Revvity Inc. Stock Advances 3.9%, Outperforms Peers

Thermo Fisher CHRO Lisa P. Britt Disposes of 11,440 Common Shares Worth $7.01 Million

Danaher Unit IDT Expands DNA Synthesis Capabilities to Support High-Diversity Assays

Thermo Fisher Scientific (TMO) Climbed, So What Is Behind The Fresh Attention?

Simply Wall St.

Steris PLC Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Danaher Corp Stock (DHR) Closed Up by 6.16% on Aug 19: A Full Analysis

Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 3.67% on Aug 19: Facts Behind the Movement

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live

Insider Move At Lifestance Health Group Sparks Investor Attention

Argenx's Myositis Data Derisk Vyvgart Opportunity, Oppenheimer Says

MT Newswires Live

Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says

MT Newswires Live

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says

MT Newswires Live

Argenx Se : Morgan Stanley Raises Target Price to $1230.00 from $1200.00

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/FMED/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FMED\",,,,,undefined,":{"symbol":"FMED","market":"US","secType":"STK","nameCN":"Fidelity Disruptive Medicine ETF","latestPrice":32.285,"timestamp":1787600503920,"preClose":32.5289,"halted":0,"volume":4089,"delay":0,"changeRate":-0.007497947978566861,"floatShares":1623806,"shares":1623806,"eps":0,"marketStatus":"Trading","change":-0.2439,"latestTime":"08-24 15:48:25 EDT","open":32.47,"high":32.47,"low":32.03,"amount":131924.126664,"amplitude":0.013526,"askPrice":32.35,"askSize":500,"bidPrice":32.31,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":32.5289,"sharesOutstanding":2323806,"nav":32.59815,"aum":52933071.5589,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.535,"preClose":32.5289,"latestTime":"19:30 EDT","volume":7,"amount":227.7956,"timestamp":1787355006413,"change":0.0061,"changeRate":0.000188,"amplitude":0},"volumeRatio":0.467686,"impliedVol":0.0806,"impliedVolPercentile":0.2229},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FMED\",,,,,undefined,":{"symbol":"FMED","floatShares":1623806,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.467686,"shares":1623806,"dividePrice":0,"high":32.47,"amplitude":0.013526,"preClose":32.5289,"low":32.03,"week52Low":23.48,"pbRate":"--","week52High":32.8877,"institutionHeld":0,"latestPrice":32.285,"eps":0,"divideRate":0,"volume":4089,"delay":0,"ttmEps":0,"open":32.47,"prevYearClose":27.05,"prevWeekClose":32.5289,"prevMonthClose":27.9952,"prevQuarterClose":28.525,"fiveDayClose":30.5871,"twentyDayClose":28.3719,"sixtyDayClose":25.2617},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FMED\",params:#limit:5,,,undefined,":[{"date":"2024-12-20","symbol":"FMED","amount":0.112,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Fidelity Disruptive Medicine ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-24"},{"date":"2024-06-21","symbol":"FMED","amount":0.001,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-21","defaultRemindTime":1718976600000,"name":"Fidelity Disruptive Medicine ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-25","payableDate":"2024-06-21","currency":"USD","dateTimestamp":1718942400000,"payDate":"2024-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FMED\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-21","recordDate":"2024-06-21","paymentDate":"2024-06-25","value":0.001,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-24","value":0.112,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FMED\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661277966","title":"European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277966","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661277966?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:15","pubTimestamp":1787584528,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts started the week slightly lower late Monday morning, declining 0.16% to 1,978.70 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet browser company Opera  and consumer goods company Unilever , which rose 1.9% and 1.8% respectively. They were followed by lender Banco Santander  and brewing company Anheuser-Busch InBev , which were up 1.2% and 1% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and biotech firm BioNTech , which dropped 5.1% and 4.2% respectively. They were followed by biopharmaceutical company argenx  and telecommunications company Nokia , which were down 2.8% and 2.6% respectively.The gainers from the UK were led by communications group WPP  and education company Pearson , which advanced 3.4% and 2.1% respectively. They were followed by alcoholic beverage company Diageo  and hospitality company Intercontinental H","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","UL","BK4535","LU0006061336.USD","TBXU","BUD.AU","BK4020","BNTX","CLLS","BK4023","BK4505","BK4183","AFG","IE00BJT1NW94.SGD","LNOK","DEO","GSIB","OPRA","IBB","SAN.AU","NCNA","AUTL","BK4111","BK4142","WPP.AU","LFGY","DGE.UK","BK4169","UN","BDRX","BK4547","IE00BFTCPJ56.SGD","ARGX","BK4009","PSO","BK4548","BK7142","WPP","FMED","BUD","NOK","BK4568","ULVR.UK","IHG","LU0320765992.SGD","BK4588","LU0124676726.USD","SAN","IEUR","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661742342","title":"Cytek Biosciences Shares Drop After Jury Says it Owes $56 Million in Damages","url":"https://stock-news.laohu8.com/highlight/detail?id=2661742342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661742342?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:09","pubTimestamp":1787580540,"startTime":"0","endTime":"0","summary":"Shares of Cytek Biosciences fell after the company said it would challenge a jury's decision to make it pay $56 million in damages in a patent infringement case.The stock was down 7.2% at $4.47 Monday. Shares are now down 12% since the start of the year.The company said Friday that in a patent infringement lawsuit brought by Beckman Coulter, a jury found in Cytek's favor on three of four claims. On the remaining claim, the jury found no literal infringement, but did find infringement under the doctrine of equivalents.The jury awarded past damages consisting of $20 million in lost profit and $36.1 million in royalties. Cytek said it would pursue post-verdict motions challenging the jury's infringement finding and the related damages.Beckman Coulter had alleged that Cytek's Aurora flow cytometers violated Beckman's patent rights for technology used in its CytoFLEX platform.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820562030.AUD","LU1923622614.USD","LU2106854487.HKD","IE000M9KFDE8.USD","LU1023059063.AUD","LU2355687059.USD","SGXZ23171101.USD","LU0289961442.SGD","SG9999001176.USD","LU0689472784.USD","BK4588","FMED","LU2125909593.SGD","BK4581","LU1057294990.SGD","SG9999001176.SGD","LU0109391861.USD","LU0289739343.SGD","BK4504","LU0820561818.USD","LU0432979614.USD","LU0157215616.USD","BK4539","LU1791710400.SGD","LU0097036916.USD","DHR","IE00BKVL7J92.USD","LU0187121727.USD","IE00BQXX3D17.EUR","SG9999013999.USD","SGXZ57979304.SGD","CTKB","BK4534","LU1917777945.USD","IE0004445239.USD","LU1923621640.USD","LU2112291526.USD","LU2244417387.USD","LU2211814178.USD","LU0320765059.SGD","LU1267930730.SGD","IE00BZ1G4Q59.USD","LU0390134368.USD","LU1551013342.USD","LU1791710582.SGD","LU1804176565.USD","BK4533","LU1551013425.SGD","LU2125910179.SGD","LU0289960550.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661820274","title":"Qiagen Names Jonathan Pratt as CEO, Effective Sept. 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2661820274","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661820274?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:45","pubTimestamp":1787579140,"startTime":"0","endTime":"0","summary":"Qiagen names Jonathan Pratt as CEO, effective Sept. 1Qiagen appointed Jonathan M. Pratt as CEO, effective Sept. 1, 2026.Pratt most recently ran Filtration Group through its sale to Parker-Hannifin in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL1Ktsf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","FMED","LU2125910179.SGD","SG9999013999.USD","LU0511384066.AUD","BK4585","QGEN","LU0289739343.SGD","LU0943347566.SGD","LU1064131342.USD","LU2063271972.USD","IE00BZ1G4Q59.USD","LU2125910336.SGD","LU1551013342.USD","LU0157215616.USD","LU2265009873.SGD","LU1804176565.USD","LU1989772840.SGD","SGXZ23171101.USD","BK4534","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","LU0107464264.USD","IE000M9KFDE8.USD","LU0208291251.USD","LU0256863902.USD","SG9999001176.USD","LU0528227936.USD","LU1923622614.USD","PH","BK4121","LU0820562030.AUD","LU0689472784.USD","LU1267930730.SGD","LU0109391861.USD","LU2433249047.HKD","LU0114720955.EUR","BK4533","IE00BKVL7J92.USD","LU1791710400.SGD","IE0004445239.USD","SGXZ57979304.SGD","DHR","LU1057294990.SGD","LU2211814178.USD","LU0320765059.SGD","LU0122379950.USD","LU0211331839.USD","LU0320765489.SGD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279382","title":"Canada's Nanalysis Q2 Revenue Edges up on Services Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279382","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279382?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:39","pubTimestamp":1787575186,"startTime":"0","endTime":"0","summary":"Canada's Nanalysis Q2 revenue edges up on services strengthOverviewCanada NMR spectrometer maker's Q2 revenue rose 1.5% yr/yr to C$9.7 mlnAdjusted EBITDA improved to C$0.9 mln from a loss in prior-yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU2063271972.USD","LU0097036916.USD","LU0289960550.SGD","LU2023250504.SGD","LU2125910336.SGD","LU1791710582.SGD","LU2106854487.HKD","SGXZ23171101.USD","BK4585","IE00BKVL7J92.USD","LU1366333091.USD","LU0107464264.USD","LU1057294990.SGD","LU2244417387.USD","SG9999013999.USD","LU0708995401.HKD","LU0312595415.SGD","LU2112291526.USD","LU0820561909.HKD","DHR","LU0122379950.USD","LU2265009873.SGD","BK4533","LU0528227936.USD","LU2355687059.USD","LU1923622614.USD","FMED","LU0820562030.AUD","SGXZ57979304.SGD","IE00BQXX3C00.GBP","IE000M9KFDE8.USD","BK4581","LU0175139822.USD","IE0004445239.USD","LU2125909593.SGD","LU0114720955.EUR","LU0289739343.SGD","LU2125909247.SGD","SG9999001176.SGD","LU0511384066.AUD","LU1804176565.USD","SG9999001176.USD","LU1791710400.SGD","LU0320765059.SGD","LU1974910355.USD","LU1923621640.USD","LU0289961442.SGD","LU2125910179.SGD","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661784220","title":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661784220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661784220?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:20","pubTimestamp":1787566808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN), Argenx Se (ARGX) and Aq...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","LU2324357040.USD","LU0109394709.USD","BK4588","IE00BJT1NW94.SGD","BK4505","BK4139","IE00B2B36J28.USD","IE0009355771.USD","LU0320765992.SGD","BK4585","IE0002141913.USD","IE00BFTCPJ56.SGD","ARGX","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE0034235188.USD","LU1983260115.SGD","TBXU","BK4007","FMED","IBB","LU0823416689.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661546290","title":"Cytek Owes Beckman Coulter $56 Mln in Cell-Analysis Patent Case, US Jury Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2661546290","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661546290?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:02","pubTimestamp":1787346151,"startTime":"0","endTime":"0","summary":"UPDATE 1-Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury saysAug 21 (Reuters)-A Delaware federal jury determined on Friday that Cytek Biosciences'CTKB.Oproducts for analyzing ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL6N44I12W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","LU0289961442.SGD","LU2211814178.USD","LU2112291526.USD","LU2265009873.SGD","DHR","LU1057294990.SGD","SGXZ23171101.USD","BK4581","BK4588","LU0157215616.USD","LU1974910355.USD","LU0107464264.USD","LU2244417387.USD","LU2125909593.SGD","LU2125909247.SGD","LU0390134368.USD","LU0882574055.USD","LU0528227936.USD","LU0820561909.HKD","SGXZ57979304.SGD","LU2063271972.USD","LU1791710582.SGD","LU1804176565.USD","LU0175139822.USD","LU0708995401.HKD","LU0289960550.SGD","FMED","LU2355687059.USD","LU0109391861.USD","LU2023250504.SGD","IE00BQXX3F31.USD","CTKB","LU1917777945.USD","LU0320765059.SGD","SG9999001176.USD","LU0097036916.USD","IE00BQXX3D17.EUR","BK4504","IE00BQXX3C00.GBP","LU0312595415.SGD","LU0432979614.USD","LU1366333091.USD","LU1791710400.SGD","LU1023059063.AUD","LU1551013342.USD","LU0672654240.SGD","IE00BZ1G4Q59.USD","LU1551013425.SGD","LU1923622614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661266450","title":"William O'Neil Initiates Thermo Fisher Scientific at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661266450","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661266450?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:18","pubTimestamp":1787303883,"startTime":"0","endTime":"0","summary":"Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $643.35, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z9505.USD","LU1791710582.SGD","TMO","FMED","LU1720051108.HKD","LU1983299246.USD","LU2125910336.SGD","LU0557290698.USD","LU2089984988.USD","TMED","LU0011850046.USD","LU0528227936.USD","LU2125909916.SGD","BK4588","IE00BQXX3D17.EUR","LU0061474960.USD","LU1923621640.USD","LU1291159041.SGD","BK4535","LU0316494557.USD","LU1815333072.USD","BK4534","LU0310800379.SGD","LU1712237335.SGD","HRTS","LU2764263203.CNY","LU2125909247.SGD","IE00BJJMRZ35.SGD","LU0823416689.USD","LU1061106388.HKD","LU1280957306.USD","BK4533","GNMX","LU1791710400.SGD","LU0708994859.HKD","LU1803068623.USD","LU1633808545.USD","LU2041044095.USD","LU0342679015.USD","LU2092937221.SGD","LU0128525929.USD","LU1023059063.AUD","LU1057294990.SGD","IE00B1BXHZ80.USD","LU0029864427.USD","LU1720051017.SGD","BK4121","LU2357305700.SGD","IE00B19Z8W00.USD","LU1548497426.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661322172","title":"Revvity Inc. Stock Advances 3.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661322172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661322172?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:35","pubTimestamp":1787258100,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Revvity Inc. rallied 3.9% to $124.13 on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.9% to 7,641.16 and Dow Jones Industrial Average falling 1.3% to 52,759.21.This was the stock's second consecutive day of gains.Revvity Inc. hit a new 52-week high, surpassing its previous peak of $122.11, which the company achieved on August 19th.The stock outperformed some of its peers, as Danaher Corp. rose 2.1% to $215.91, IDEXX Laboratories Inc. fell 2.9% to $545.86, and Agilent Technologies Inc. rose 0.57% to $156.30.Trading volume totaled 2.3 million, compared to the 50-day average of 1.5 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1804176565.USD","LU1917777945.USD","BK4504","IE00BKVL7J92.USD","LU0289961442.SGD","LU0097036916.USD","LU0157215616.USD","BK4581","LU1791710582.SGD","LU1551013425.SGD","GB00B4QBRK32.GBP","LU1057294990.SGD","LU1974910355.USD","LU0109391861.USD","LU1061106388.HKD","LU2125909247.SGD","LU2355687059.USD","BK4121","BK4585","SGXZ23171101.USD","LU1941712348.USD","LU2229751404.USD","LU0820561818.USD","IE00BLDYK493.USD","LU2063271972.USD","PAWZ","LU1923621640.USD","LU1791710400.SGD","LU2041044095.USD","LU0175139822.USD","LU1165135440.EUR","LU0289739343.SGD","LU2125910336.SGD","FMED","LU1941712264.USD","LU0347712357.USD","LU0672654240.SGD","A","IE00BN0W2W23.USD","LU2112291526.USD","DHR","LU2404859741.USD","RVTY","LU2089279066.USD","BK4082","LU0289960550.SGD","IE00BN0W2T93.GBP","IDXX","SG9999013999.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661234283","title":"Thermo Fisher CHRO Lisa P. Britt Disposes of 11,440 Common Shares Worth $7.01 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661234283","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661234283?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:03","pubTimestamp":1787256208,"startTime":"0","endTime":"0","summary":"Thermo Fisher CHRO Lisa P. Britt disposes of 11,440 common shares worth $7.01 millionLisa P. Britt, Sr. VP and Chief HR Officer, sold 11,440 Thermo Fisher shares on Aug. 19, 2026 at USD 613.12.Transac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLVzrkP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Thermo Fisher CHRO Lisa P. Britt Disposes of 11,440 Common Shares Worth $7.01 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9505.USD","IE00BQXX3C00.GBP","TMO","FMED","LU1983299246.USD","IE0009355771.USD","LU1670627923.USD","LU2468319806.SGD","LU2089984988.USD","TMED","LU1267930573.SGD","LU2125909916.SGD","BK4588","LU2720916845.USD","LU0070302665.USD","IE00BQXX3D17.EUR","LU0266013472.USD","LU1989771016.USD","LU0957791311.USD","LU0316494557.USD","BK4548","LU2125909593.SGD","LU0310800379.SGD","HRTS","BK4581","LU1064131342.USD","IE00BJJMRZ35.SGD","LU1854104046.USD","LU2764262908.HKD","LU0823416689.USD","LU2360108059.USD","IE00BJT1NW94.SGD","IE00BKPKM429.USD","GNMX","LU1791710400.SGD","LU2125909759.SGD","LU1803068623.USD","LU1633808545.USD","LU0342679015.USD","LU0128525929.USD","LU1023059063.AUD","LU2063271972.USD","LU2543165471.USD","LU2125910179.SGD","LU1623119135.USD","LU2433249047.HKD","LU1720051017.SGD","LU1988902786.USD","BK4585","LU1548497426.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660826442","title":"Danaher Unit IDT Expands DNA Synthesis Capabilities to Support High-Diversity Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2660826442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660826442?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:55","pubTimestamp":1787230539,"startTime":"0","endTime":"0","summary":"Danaher unit IDT expands DNA synthesis capabilities to support high-diversity assaysDanaher unit Integrated DNA Technologies expanded DNA synthesis capabilities to cover higher-diversity designs, larg","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4Z6bb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","IE000M9KFDE8.USD","LU0289960550.SGD","LU0820561909.HKD","LU1023059063.AUD","BK4588","LU0097036916.USD","BK4121","LU0114720955.EUR","IE0004445239.USD","LU0390134368.USD","LU1923622614.USD","LU1974910355.USD","LU1061106388.HKD","LU2125910336.SGD","LU2244417387.USD","SG9999013999.USD","LU0672654240.SGD","LU1551013425.SGD","LU2125909247.SGD","SGXZ57979304.SGD","LU0157215616.USD","LU1917777945.USD","LU0689472784.USD","BK4533","LU2265009873.SGD","LU1267930730.SGD","FMED","LU1791710400.SGD","IE00BQXX3F31.USD","BK4581","DHR","LU2023250504.SGD","IE00BKVL7J92.USD","LU0107464264.USD","LU0312595415.SGD","LU0432979614.USD","LU0320765059.SGD","LU1804176565.USD","LU2355687059.USD","LU0187121727.USD","LU0122379950.USD","LU2112291526.USD","BK4504","LU1791710582.SGD","IE00BZ1G4Q59.USD","SG9999001176.USD","LU0528227936.USD","IE00BQXX3D17.EUR","LU0943347566.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660834352","title":"Thermo Fisher Scientific (TMO) Climbed, So What Is Behind The Fresh Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660834352","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660834352?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:32","pubTimestamp":1787214754,"startTime":"0","endTime":"0","summary":"Thermo Fisher Scientific (TMO) drew fresh attention after reporting quarterly revenue and earnings that exceeded analyst expectations, alongside completing a large Parkinson's proteomics project with The Michael J. Fox Foundation.\nSee our latest analysis for Thermo Fisher Scientific.\nThermo Fisher Scientific's recent earnings beat and the completion of the Parkinson's proteomics project have coincided with strong momentum, including a 16.6% 30 day share price return and a 24.5% 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/97023-main-header/1756189961534","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/97023-main-header/1756189961534"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-climbed-so-what-is-behind-the-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-climbed-so-what-is-behind-the-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1989771016.USD","FMED","LU2092937221.SGD","LU0708994859.HKD","DCF","IE00B19Z9505.USD","BK4533","LU1670628061.USD","LU2764263039.SGD","LU2125909759.SGD","LU0096362180.USD","LU2125910336.SGD","LU1791710582.SGD","IE00B19Z8X17.USD","LU1983299246.USD","LU0128525929.USD","LU1023059063.AUD","LU2125909247.SGD","LU0882574055.USD","LU2360108059.USD","LU2720916845.USD","LU2764263203.CNY","LU1923621640.USD","LU0432979614.USD","LU0070302665.USD","LU2298321311.HKD","LU1720051017.SGD","IE00BQXX3F31.USD","LU2125909916.SGD","LU2089984988.USD","LU1923622614.USD","LU2125909593.SGD","GB00BDT5M118.USD","LU2543165471.USD","LU2764262908.HKD","LU0345770993.USD","IE00BJJMRZ35.SGD","GNMX","LU0345770308.USD","IE00BFTCPJ56.SGD","TMO","BK4566","LU1815333072.USD","LU1670627923.USD","HRTS","TMED","IE0034235188.USD","BK4585","LU0320765489.SGD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660756114","title":"Steris PLC Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2660756114","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660756114?lang=en_us&edition=fundamental","pubTime":"2026-08-20 05:04","pubTimestamp":1787173440,"startTime":"0","endTime":"0","summary":"DJ Steris PLC Stock Underperforms Wednesday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Steris PLC  advanced 1.95% to $236.91 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.21% to 7,707.98 and the Dow Jones Industrial Average  rising 0.22% to 53,463.05.This was the stock's second consecutive day of gains.Steris PLC closed 12.07% below its 52-week high of $269.44, which the company reached on January 16th.The stock underperformed when compared to some of its competitors Wednesday, as Thermo Fisher Scientific Inc.  rose 4.16% to $613.54, Danaher Corp.  rose 5.97% to $211.50, and Becton Dickinson & Co.  rose 3.78% to $187.60.Trading volume  remained 84,827 below its 50-day average volume of 791,095.Data source: Dow Jones Market Data, FactSet. Data compiled August 19, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FMED","BK4588","LU0477156797.USD","LU2764263039.SGD","LU0528227936.USD","LU1548497426.USD","BK4581","LU1712237335.SGD","LU2211815571.USD","LU2125910336.SGD","BK4504","IE00B19Z8X17.USD","LU1983299246.USD","LU1551013425.SGD","IE00B19Z8W00.USD","LU0072461881.USD","STE","LU2298321311.HKD","LU0342679015.USD","LU0208291251.USD","LU2355687059.USD","LU0708995401.HKD","LU0648000940.SGD","BDX","LU2125909593.SGD","DHR","LU1201861165.SGD","LU0130103400.USD","LU0878866978.SGD","LU0943347566.SGD","BK4535","LU0433182093.SGD","IE00BKVL7J92.USD","LU2265009873.SGD","IHI","GNMX","LU0985320562.USD","LU0345770308.USD","LU1057294990.SGD","LU2433249047.HKD","IE00BFTCPJ56.SGD","LU1633808545.USD","TMO","LU1489326972.SGD","HRTS","TMED","LU0289739343.SGD","LU1023059063.AUD","BK4548","LU1150488135.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473613","title":"Danaher Corp Stock (DHR) Closed Up by 6.16% on Aug 19: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473613","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473613?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:15","pubTimestamp":1787170543,"startTime":"0","endTime":"0","summary":"• Danaher reported second-quarter revenue and adjusted earnings exceeding Wall Street consensus estimates.\n• Julie Sawyer Montgomery was appointed as the new chief executive officer.\n• Danaher generated $24.57B in annual revenue with $3.61B in net profit.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262119120-market-movers-dhr-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710582.SGD","SG9999004303.SGD","LU2112291526.USD","LU1804176565.USD","LU1267930730.SGD","BK4533","LU0289960550.SGD","LU1917777945.USD","LU2063271972.USD","LU2125909247.SGD","LU1023059063.AUD","LU1366333091.USD","LU0175139822.USD","IE00BKVL7J92.USD","BK4121","LU0528227936.USD","LU2125909593.SGD","IE0004445239.USD","LU0511384066.AUD","LU1923622614.USD","FMED","SGXZ57979304.SGD","LU0097036916.USD","LU2211814178.USD","SG9999013999.USD","BK4581","BK4585","LU0882574055.USD","LU2125910336.SGD","LU0820561818.USD","LU2125910179.SGD","LU1061106388.HKD","LU1551013425.SGD","IE00BQXX3F31.USD","LU0432979614.USD","LU0820562030.AUD","LU1057294990.SGD","BK4534","IE00BQXX3C00.GBP","LU0390134368.USD","LU0672654240.SGD","LU0708995401.HKD","LU1923621640.USD","LU0943347566.SGD","LU0114720955.EUR","DHR","LU2355687059.USD","LU1791710400.SGD","IE00BZ1G4Q59.USD","LU0122379950.USD","IE000M9KFDE8.USD","LU1551013342.USD","BK4588","LU0289961442.SGD","LU2244417387.USD","LU0312595415.SGD","LU1974910355.USD","IE00BQXX3D17.EUR","LU0109391861.USD","LU2023250504.SGD","LU2265009873.SGD","SGXZ23171101.USD","LU0187121727.USD","SG9999001176.USD","LU0289739343.SGD","LU0689472784.USD","BK4504","LU2106854487.HKD","SG9999001176.SGD","LU0107464264.USD","LU0157215616.USD","LU0320765059.SGD","LU0820561909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660427589","title":"Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 3.67% on Aug 19: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660427589","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660427589?lang=en_us&edition=fundamental","pubTime":"2026-08-20 01:15","pubTimestamp":1787159744,"startTime":"0","endTime":"0","summary":"• Thermo Fisher raised its full-year outlook following strong second-quarter financial results.\n• The company sold its microbiology business to Astorg for over one billion dollars.\n• Institutional managers and hedge funds recently built fresh positions in the company.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262118659-market-movers-tmo-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0528227936.USD","LU0432979614.USD","LU0882574055.USD","LU0114720955.EUR","LU1989771016.USD","LU0096362180.USD","LU1791710582.SGD","GB00BDT5M118.USD","LU1815333072.USD","LU2298321311.HKD","IE00BJT1NW94.SGD","BK4535","LU2125910336.SGD","BK4566","GNMX","TMO","IE00B19Z8W00.USD","LU0029864427.USD","LU1988902786.USD","LU0957791311.USD","LU2764263203.CNY","LU1548497426.USD","LU0234572021.USD","HRTS","LU1064131342.USD","IE00BFTCPJ56.SGD","LU1803068623.USD","IE00B1BXHZ80.USD","LU2211814178.USD","TMED","LU1983299246.USD","LU1854104046.USD","IE00BQXX3D17.EUR","LU0208291251.USD","LU0320765489.SGD","BK4585","LU2468319806.SGD","LU1280957306.USD","LU1712237335.SGD","IE0034235188.USD","LU1057294990.SGD","LU1720051017.SGD","LU1291159041.SGD","LU0070302665.USD","LU0708994859.HKD","LU2360108059.USD","LU1791710400.SGD","LU1153585028.USD","IE0002141913.USD","BK4534","LU2125909916.SGD","LU0011850046.USD","LU2764263039.SGD","LU2063271972.USD","LU0557290698.USD","LU1670628061.USD","LU1023059063.AUD","LU0122379950.USD","LU0310800379.SGD","LU2092937221.SGD","LU0128525929.USD","BK4581","LU1623119135.USD","FMED","LU0316494557.USD","LU2433249047.HKD","LU2041044095.USD","LU2543165471.USD","LU1267930573.SGD","LU2357305700.SGD","LU0345770993.USD","LU2125909247.SGD","LU0342679015.USD","LU2720916845.USD","BK4588","LU1670627923.USD","LU2125909759.SGD","LU0061474960.USD","LU1923622291.USD","LU1720051108.HKD","IE00BQXX3C00.GBP","IE00B4R5TH58.HKD","LU1854103824.USD","IE00BKPKM429.USD","BK4533","LU1923622614.USD","IE00B19Z9505.USD","LU1923621640.USD","IE00BQXX3F31.USD","LU0266013472.USD","LU0640476718.USD","LU1061106388.HKD","LU0345770308.USD","LU2112291526.USD","LU0823416689.USD","LU2764262908.HKD","LU2211815571.USD","IE00B2B36J28.USD","BK4121","IE00BJJMRZ35.SGD","IE00B19Z8X17.USD","LU2264538146.SGD","IE0009355771.USD","LU2125909593.SGD","BK4548","LU1633808545.USD","LU2125910179.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421716","title":"European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421716","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421716?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:18","pubTimestamp":1787152727,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.68% to 1,973.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech  and biopharmaceutical company Grifols , which advanced 24% and 5.6% respectively. They were followed by semiconductor company Sequans Communications  and biopharmaceutical company argenx , which rose 3.3% and 3% respectively.The decliners from continental Europe were led by internet browser company Opera  and biotech firm Evaxion , which fell 7.9% and 6% respectively. They were followed by accommodations booking site Trivago  and telecommunications company Nokia , which were down 4.3% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and mining company BHP Group , which increased 9.2% and 4.5% respectively. They were followed by software firm Endava  and biopharmaceutical company Bicycle Therapeutics , w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","IBB","IE00BMPRXN33.USD","LFGY","IE00BJT1NW94.SGD","BDRX","XBIX","BK4585","SLX","IE00B4R5TH58.HKD","AUTL","DAVA","IE0009355771.USD","GRFS","LU0889565916.HKD","LU2324357040.USD","TRVG","DAVA.AU","SQNS","AFG","BK4547","SNN","LU0006061336.USD","LU0109394709.USD","BK4548","IEUR","EPV","TRIB","ARGX","IE00BJJMRZ35.SGD","LU0823416689.USD","BCYC","NVIB","IE00B2B36J28.USD","BNTX","COAL","FMED","BHP.AU","BHP","OPRA","LU0300736062.USD","NOK","BK4117","PUK","LNOK","BK4588","TBXU","LU0648005311.SGD","EVAX","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660249416","title":"Insider Move At Lifestance Health Group Sparks Investor Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2660249416","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660249416?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:09","pubTimestamp":1787105395,"startTime":"0","endTime":"0","summary":"New insider activity at Lifestance Health Group ( ($LFST) ) has taken place on August 18, 2026. Director Teresa DeLuca of Lifestance Health Group h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-move-at-lifestance-health-group-sparks-investor-attention-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-move-at-lifestance-health-group-sparks-investor-attention-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LFST","BK4196","FMED","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660495742","title":"Argenx's Myositis Data Derisk Vyvgart Opportunity, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660495742","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660495742?lang=en_us&edition=fundamental","pubTime":"2026-08-18 23:35","pubTimestamp":1787067344,"startTime":"0","endTime":"0","summary":"Argenx's  phase 3 data on Vyvgart reduce the uncertainty around its potential $1.5 billion to $2 billion autoimmune myositis opportunity, Oppenheimer said.The phase 3 study of Vyvgart achieved its primary endpoint for the combined dermatomyositis and immune-mediated necrotizing myopathy, or IMNM, population, the investment firm said in a Monday note, noting IMNM as the therapy's \"most derisked\" path to approval.In the IMNM subgroup, Vyvgart-treated patients showed a 14.8-point greater improvement in mean Total Improvement Score versus placebo at week 52, a statistically significant result with a p-value of 0.0048, Oppenheimer added.The results are a testament to the company's pipeline-in-a-product strategy, bringing it closer to entering rheumatology as a second therapeutic category, according to the noteOppenheimer raised its price target on argenx to $1,100 from $1,037, while keeping its outperform outlook.Shares of Argenx were up 1.1% in Tuesday trading.Price: 998.83, Change: +10.99","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823416689.USD","IE0009355771.USD","IBB","IE0034235188.USD","ARGX","IE00BFTCPJ56.SGD","BK4505","IE00BJJMRZ35.SGD","BK4588","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","FMED","LU1983260115.SGD","LU0109394709.USD","IE00B2B36J28.USD","BK4127","LU0320765992.SGD","BK4585","OPY","LU2324357040.USD","TBXU","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660495503","title":"Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660495503","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660495503?lang=en_us&edition=fundamental","pubTime":"2026-08-18 23:06","pubTimestamp":1787065592,"startTime":"0","endTime":"0","summary":"Argenx's (ARGX) Vyvgart Hytrulo is likely to get approval from the US Food and Drug Administration for adults with immune-mediated necrotizing myopathy and dermatomyositis, RBC Capital Markets analyst","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","BK4585","IE00BFTCPJ56.SGD","LU0109394709.USD","ARGX","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LABU","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4588","IE0034235188.USD","LU0889565916.HKD","BK4139","LU2324357040.USD","FMED","IBB","IE00BJT1NW94.SGD","BK4505","LU1983260115.SGD","LU0823416689.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660070493","title":"Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660070493","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660070493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:54","pubTimestamp":1787064888,"startTime":"0","endTime":"0","summary":"Argenx's (ARGX) latest myositis data strengthened the outlook for efgartigimod, particularly in immune-mediated necrotizing myopathy, resulting in higher probability-of-success assumptions, Morgan Sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","IE00BJT1NW94.SGD","BK4585","IE00B4R5TH58.HKD","BK4563","IE0009355771.USD","IMNM","BK4505","LU0889565916.HKD","LU2324357040.USD","IE0034235188.USD","LU0109394709.USD","ARGX","IE00BJJMRZ35.SGD","LU0823416689.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","FMED","BK4588","LU0320765992.SGD","TBXU","BK4139","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660646056","title":"Argenx Se : Morgan Stanley Raises Target Price to $1230.00 from $1200.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2660646056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660646056?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:12","pubTimestamp":1787058744,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nAZN4TEZHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","IBB","IE0002141913.USD","BK4588","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","LU2324357040.USD","FMED","ARGX","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","TBXU","IE00BJT1NW94.SGD","LU1983260115.SGD","IE00BJJMRZ35.SGD","IE0034235188.USD","LU0109394709.USD","BK4505","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}